NextPlat (NXPL) Curent Deferred Tax Liability (2017)

NextPlat's (NXPL) quarterly Curent Deferred Tax Liability came in at $23459.0 in Q4 2017.

Analysis

NextPlat (NXPL) Curent Deferred Tax Liability (2017) Analysis & Trends

NextPlat (NXPL) has reported Curent Deferred Tax Liability for 1 consecutive years, with $23459.0 the latest figure, recorded in Q4 2017.

On a quarterly basis, Curent Deferred Tax Liability changed N/A year-over-year to $23459.0 in Q4 2017; TTM through Dec 2017 was $23459.0, a N/A change from a year earlier, with the FY2017 full-year figure at $23459.0, changed N/A from the prior year.
Curent Deferred Tax Liability was $23459.0 for Q4 2017 at NextPlat.
Over five years, Curent Deferred Tax Liability peaked at $23459.0 in Q4 2017 and troughed at $23459.0 in Q4 2017.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Curent Deferred Tax Liability (Qtr)
1	Teva Pharmaceutical Industries	42.34 Bn	38.68 Bn	2.15 Bn	-
2	Viatris	19.39 Bn	18.50 Bn	1.46 Bn	-
3	Dr Reddys Laboratories	9.99 Bn	9.85 Bn	396.53 Mn	-
4	Amneal Pharmaceuticals	5.57 Bn	5.53 Bn	334.51 Mn	-
5	Bausch Health Companies	2.45 Bn	1.58 Bn	2.10 Bn	-
6	Ani Pharmaceuticals	1.70 Bn	1.34 Bn	165.89 Mn	-
7	Alvotech	1.66 Bn	1.52 Bn	2.56 Mn	-
8	Amphastar Pharmaceuticals	985.90 Mn	695.77 Mn	93.47 Mn	-
9	Fennec Pharmaceuticals	434.07 Mn	392.82 Mn	17.15 Mn	-
10	NextPlat	24.77 Mn	12.93 Mn	4.69 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2017	23,459.00